Fig. 3: Combination of TPL and ABT-199 displays a superior antileukemic activity in vivo.
a–d BALB/C nude mice were injected subcutaneously with 5.8 × 106 MOLM-13 cells at the right flank. Once the tumor volume reached to ~75 mm3, mice were randomly assigned to four groups (n = 5/group) including control (ctrl), TPL, ABT-199, and combination (combo), and treated for 2 consecutive weeks with vehicle (0.2% methyl cellulose and 0.1% Tween-80 in PBS), TPL (0.5 mg/kg/day, intraperitoneal injection), ABT-199 (50 mg/kg/day, oral gavage), or combination of TPL and ABT-199, respectively. At the end of the study, images of mice and removed tumors were captured a, and tumor volume b and weight c were measured. During treatment, body weight of mice was monitored daily d. Data represent the mean ± SD. e, f NOD-SCID IL-2Rγ null mice were injected intravenously with 4 × 106 MV4–11-luciferase-GFP cells. After engraftment was confirmed, mice were randomly assigned to four groups (n = 7/group) and treated daily with vehicle (ctrl), TPL (0.5 mg/kg/day, intraperitoneal injection), ABT-199 (50 mg/kg/day, oral gavage) or their combination (Combo). The tumor burden was monitored by bioluminescent imaging at designated time points e. Animal survival was analyzed using the Kaplan–Meier survival curve f. *P < 0.05, **P < 0.01.
